Comprehensive analysis of real-world data shows significant clinical and medico-economic advantages of Implicity’s universal, alert-based remote monitoring platform

 IMPLICITY, a leader in remote patient monitoring and cardiac data management solutions, unveiled new findings from its EVIDENCE-RM study. Leveraging extensive data from the French National Health Data System (SNDS), the study demonstrated clear clinical and medico-economic benefits associated with Implicity’s universal monitoring system (UMS) compared to conventional, manufacturer-specific systems, including Abbott, Biotronik, Boston Scientific, and Medtronic.

Health Technology Insights: Advancium Backs SARM1 Inhibitor Research for Rare Eye Disease

The study, recently published in Heart Rhythm, analyzed clinical outcomes and costs for over 69,000 patients with implantable cardioverter-defibrillators (ICDs) and defibrillators with cardiac resynchronization therapy (CRT-Ds). Patients remotely monitored using Implicity’s platform showed increased survival rates and a reduction in both the number and duration of all-cause and heart failure-related hospitalizations, resulting in substantial healthcare cost reductions. Key findings attributed to Implicity’s IM009² platform include:

Health Technology Insights: Protega, OPOS Partner to Boost Pain Care and Patient Education

  • 26% reduction in mortality (HR, 0.74; 95% CI, 0.73–0.77; P=.001)
  • 4% decrease in HF hospitalizations, total corrected healthcare costs, and mean duration of hospitalization
  • 17.8% decrease in hospital-related costs, primarily driven by decreased costs in cardiovascular disease care
  • Incremental Cost-Effectiveness Ratio (ICER) of approximately -$112 USD (-103€) per Day Alive and Out of Hospital (DAOH) based on the French Healthcare System

“Managing patients with ICDs and CRTs presents considerable challenges, since they are at high risk of hospitalization due to arrhythmias and heart failure,” said Dr. Niraj Varma, Professor of Medicine and Director, Cardiac Pacing & Tachyarrhythmia Devices at the Cleveland Clinic. “The EVIDENCE-RM study clearly demonstrates that a universal monitoring solution operating alert-based remote monitoring can significantly reduce these risks, improving patient outcomes and substantially lowering healthcare costs. This is an important advancement in our ability to proactively manage patients with ICDs and CRTs.”

“These findings mark a pivotal moment in remote cardiac care and prove Implicity’s effectiveness with unparalleled clinical results,” stated Implicity CEO Dr. Arnaud Rosier. “A 26% reduction in mortality and better use of healthcare resources highlight the impact of universal remote monitoring, driven by AI, over fragmented manufacturer-specific systems. Implicity is committed to driving innovation so that every cardiac patient receives proactive, efficient care.”

Health Technology Insights: Koan Health to Launch Financial Impact Module for ACOs

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – PR Newswire